Search
for
Sort by
Research 571–600 of 1000+
- Nutrition and Hair
- Pregnancy and Skin
- Bioavailability File: Bicalutamide
- Niosomes as a propitious carrier for topical drug delivery
- Niosomes as Carrier in Dermal Drug Delivery
- Flares of systemic lupus erythematosus during pregnancy and the puerperium: prevention, diagnosis and management
- Harmless Herbs? A Review of the Recent Literature
- Herbal Therapy in Dermatology
- Linking diet to acne metabolomics, inflammation, and comedogenesis: an update
- Liposomes in cosmeceutics
- Finasteride
- Nutrition Strategy and Life Style in Polycystic Ovary Syndrome—Narrative Review
- The Effect of 5 -Reductase Inhibitors on Erectile Function
- Potential Health Risks Associated with Cosmetics and Personal Care Products: An Overview
- Benign Cutaneous Eruptions After Transplantation
- Encapsulación en ciclodextrinas de compuestos con actividad frente a la alopecia androgénica masculina.
- Follikelhormone
- Infertility: Evaluation and Initial Management
- Applications and Risks of Nanomaterials Used in Regenerative Medicine, Delivery Systems, Theranostics, and Therapy
- Hair Biology and Care Product Ingredients from Marine Organisms
- Topical and nutricosmetic products for healthy hair and dermal antiaging using “dual‐acting” (2 for 1) plant‐based peptides, hormones, and cannabinoids
- Acne and sebaceous gland function
- Biochemical and Structural Characteristics, Gene Regulation, Physiological, Pathological and Clinical Features of Lipocalin-Type Prostaglandin D2 Synthase as a Multifunctional Lipocalin
- Pathophysiology of Androgenetic Alopecia and Implications for Treatment: An Overview of Current Literature
- Gray Hair: From Preventive to Treatment
- Dermatological Changes during Menopause and HRT: What to Expect?
- Benefits of Testosterone Replacement and Methods of Substitution
- Isochromosome Mosaic Turner Syndrome: A Case Report
- Management of Sexual Dysfunction in Postmenopausal Breast Cancer Patients Taking Adjuvant Aromatase Inhibitor Therapy
- NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders